Weill Cornell Medicine Develops AI Method for Blood Cancer Assessment
Researchers at Weill Cornell Medicine have introduced a new AI-based method to evaluate patients with myelodysplastic neoplasms (MDS), a type of blood cancer. This innovative approach involves analyzing the spatial architecture of bone marrow cells to generate a score that indicates disease severity. MDS primarily affects older adults, with about one-third of cases progressing to acute myeloid leukemia. The current diagnostic methods often leave room for ambiguity, but the new AI tool aims to provide clearer insights. The MDS-Microarchitectural Perturbation Score (MDS-MAPS) evaluates 82 features of bone marrow samples, using standard laboratory assays and imaging technologies. This method could potentially be adopted by most hospital pathology departments to improve patient prognosis and treatment strategies. 
